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Aquaretic effects of the nonpeptide V2 antagonist OPC-3 1260 in
hydropenic humans
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Aquaretic effects of the nonpeptide V2 antagonist OPC-3 1260 in hydro-
penic humans. The antidiuretic action of arginine vasopressin (AVP) is
mediated by interaction with renal V2 receptors. A nonpeptide V2
receptor antagonist, OPC-31260, has recently been developed. In this
study, the effects of OPC-3 1260 on the excretion of water and electrolytes
were investigated in normal subjects who were under water restriction.
Since the clinical circumstances in which a V2 antagonist would be useful
generally would be in patients with concentrated urine, a hydropenic state
with nearly maximally concentrated urine was selected as the experimental
condition. Intravenous injection of OPC-31260 caused an increase in urine
volume and a decrease in urine osmolality in a dose dependent manner
without any significant changes in the excretion of sodium and other
electrolytes. A high dose of OPC-31260 (1 mg/kg body wt) caused free
water excretion equivalent to that obtained during maximum diuresis after
water loading, followed by an increase in plasma sodium and AVP
concentration. Excretion of urea increased transiently during diuresis.
Thus, OPC-31260 is demonstrated to be the first V2 antagonist which
exhibits water diuresis (aquaresis) in hydropenic humans with endogenous
AVP secretion and maximally concentrated urine. The drug will be useful
as an aquaretic in the treatment of some types of hyponatremia where
there is excess AVP and water retention.
Arginine vasopressin (AVP) increases water reabsorption via
the renal collecting ducts, causing antidiuresis and urine concen-
tration. This antidiuretic action of AVP is mediated by interaction
with renal V2 receptors.
Peptide V2 antagonists, vasopressin analogues, have been de-
signed and developed by Manning and Sawyer [1] and others.
These peptide V2 antagonists were shown to cause water diuresis
(aquaresis) in vivo in some animal species [4]. In humans,
however, such aquaresis did not occur due to the manifestation of
their V2 agonist action [5]. These facts demonstrated that there
are species differences in the action of V2 antagonists, and that
their action on humans cannot be predicted based on the results
of animal experiments.
A nonpeptide vasopressin V2 receptor antagonist, OPC-31260
{(±)-5-dimethylamino-1-(4-[2-methylbenzoylamino]benzoyl)-2, 3,
4,5-tetrahydro-1H-benzazepin hydrochloride}, has recently been
developed [6]. This V2 antagonist selectively and competitively
inhibited AVP binding to renal cell membrane V2 receptors in
vitro, and also antagonized AVP action in vivo, causing aquaresis
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in rats [6], and also in humans who were hydrated by taking an
appropriate amount of water before and during the study to avoid
dehydration [7].
However, the hydrated state of the subjects may have a major
impact on the effects of OPC-31260. Therefore, it is both suitable
and necessary to investigate the effects of OPC-31260 in hydro-
penic subjects, since the hydropenic state is, in aspects of concen-
trated urine and AVP secretion, closer to the pathophysiological
conditions under which OPC-31260 will be clinically applied, such
as the syndrome of inappropriate secretion of ADH (SIADH) or
edematous diseases.
In hydropenia, plasma AVP concentration is increased and the
number of V2 receptors occupied by AVP may be increased.
Moreover, the antidiuretic sensitivity of the kidney to AVP is
increased by the increased medullary osmolality and by the
change in renal hemodynamics with modulated prostaglandin
production. Therefore, a V2 antagonist may be much less effective
in a hydropenic state.
The purpose of this study was to assess the aquaretic action of
OPC-31260 in normal human subjects under water restricted
conditions, in which the plasma AVP concentration was relatively
increased and the urine was almost maximally concentrated. In
addition, under certain conditions, AVP has some effects on the
urinary excretion of cyclic AMP and prostaglandins, the plasma
level of human atrial natriuretic peptides (h-ANP), and renin-
angiotensin-aldosterone (RAA) system activity [8, 9], and these
effects may in turn modulate water and solute excretion. In fact,
OPC-31260 was reported to cause water diuresis with an increase
in sodium excretion in the previous paper [7], which suggests some
effects other than those of a pure V2 antagonist. However, the
effects of OPC-3 1260 on these parameters are not well known and
were therefore investigated in the present study. Since aquaresis
by a V2 antagonist in humans in an antidiuretic and hydropenic
condition has not been demonstrated, if this V2 antagonist
possesses an aquaretic action in such a condition, it will offer great
potential for clinical application.
Methods
Subjects were nine adult male volunteers between 22 and 26
years of age (23.2 1.5, mean SD) and weighing between 51.6
and 71.9 kg (60.4 6.3, mean SD). Before initiation of the
study, written informed consent was obtained from each subject,
and the study was approved by the ethical committee for human
study.
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Fig. 1. Effect of OPC-31260 on urine volume. The drug was injected at
time zero. Symbols are: (0) control group, () low dose group with 0.1
mg/kg of OPC-31260, (S) high dose group with 1.0 mg/kg of OPC-31260.
*p < 0.05, P < 0.01 compared with control group. Bars indicate mean
SEM, N = 5.
The subjects had undergone routine physical examination,
blood and urine tests, and electrocardiography, and all findings
were within normal limits. The study was conducted in an
air-conditioned room with the subjects in a supine position, except
during the time of urine voiding.
Protocol
The following procedure was repeated twice on nine subjects at
two week intervals, where each subject was to be assigned to two
different groups: the control group (N = 6) was dosed with
vehicle, the low dose group (N = 6) with 0.1 mg/kg body wt of
OPC-31260 (1 mg/mI), and the high dose group (N =6) with 1.0
mg/kg body wt of OPC-3 1260 (5 mg/mi). The subjects abstained
from eating from 18:00 and from drinking water from 23:00 on the
day before initiation of the experiment to 13:00 on the day of
experiment. On the day of the experiment, a vein in the antecu-
bital region was cannulated, and the catheter was connected to a
two-way stopcock to allow blood sampling. The subjects urinated
at 7:00 and at 9:00, and then each subject was given a single
intravenous injection of OPC-31 260 or vehicle via a cubital vein.
During the four hour period after the injection, blood and urine
samples were collected every 30 or 60 minutes for assaying blood
and urine osmolality, electrolytes and hormones. Heart rate and
blood pressure were monitored, as were the respiratory rate, body
temperature and electrocardiogram.
Measurements
Serum and urine osmolality was determined by the freezing
point depression method using an osmometer (3D2, Advanced
Instruments, USA). Urinary sodium (Na) and potassium (K)
concentrations were measured using a flame photometer (775A,
Hitachi Co., Ltd., Japan), Serum Na and K concentrations were
measured using an autoanalyzer equipped with ion specific elec-
trodes (ION-15OAC, Joko Co., Ltd., Japan). Serum and urinary
levels of creatinine, urea, uric acid, calcium (Ca) and phosphate
(P) were measured using an autoanalyzer (736—10, Hitachi Co.,
Ltd.).
Plasma and urinary arginine vasopressin (AVP) and plasma
atrial natriuretic peptide (h-ANP) were extracted and assayed by
radioimmunoassay (RIA), as described previously [7, 101. Plasma
and urinary cyclic AMP (cAMP) were determined by RIA using
an RIA kit (Yamasa, Japan). Plasma renin activity (PRA) was
determined by RLA using a Gamma Cort [1251] PRA Kit (Baxter
Ltd., Round Lake, IL, USA). Plasma aldosterone was determined
by RIA using an RIA kit (SPAC-S Aldosterone Kit, Daiichi
Radioisotope Lab., Japan). Plasma angiotensin II was determined
by RIA (MSS Kanagawa, Japan). Plasma epinephrine and nor-
epinephrine levels were measured by the HPLC method (HLC-
8030, TOSOH, Japan). Urinary concentrations of prostaglandin
E2 (PGE2), thoromboxane B2 (TXB2) and 6-keto-prostaglandin
F1, (6-keto-PGF1,) were determined by RIA using RIA kits
(Amersham International PlC, USA).
Statistics
All data are shown as mean SEM. When the subjects could not
void urine regularly in time, their data were omitted from the
calculations. All statistical tests used for analysis were two-sided
tests using Ea = 0.05. For the endpoints presented in this report,
Scheffe's multiple comparison procedure was conducted to adjust
the type I error rate for multiple testing between the vehicle-
treated group and the OPC-treated groups, which were comprised
of both a high dose and a low dose group, within each time frame.
Further, Dunnett's multiple comparison procedure was conducted
for multiple testing between the pre-administration time frame
and the other time frames within each treatment group under the
assumption that each time frame data were independent. The
statistical significance level was set at P < 0.05.
Results
The effect of OPC-31260 on urine volume is shown in Figure 1.
In the high dose group, urine volume increased by about eight
times, reaching a maximum of 7.1 1.3 ml/min at 0.5 to 1 hour
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Fig. 2. Effect of OPC-31260 on urine osmolality (U0,,,). Symbols and
statistical comparisons are the same as those in Figure 1. Bars indicate
mean SEM, N = 5.
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after the OPC-31260 injection and returning to the control level
after four hours. The cumulative urine volumes for the four hour
period following injection were 133 18 ml in the control group,
280 99 ml in the low dose group and 672 124 ml in the high
dose group (P < 0.01 compared with the control group).
Changes in urine osmolality are shown in Figure 2. In the high
dose group, urine osmolality declined from 918 60 to a
minimum of 99 2 mOsm/kg H20 (0.5 to 1 hr). In the low dose
group, urine osmolality declined from 908 71 to a minimum of
651 164 mOsm/kg H20 (0.5 to 1 hr), while urine remained
almost maximally concentrated in the control group.
Changes in free water clearance (CH20) are shown in Figure 3,
demonstrating that the increase in urine volume was based
primarily on the increase in C20. However, osmolar clearance
(Cosm) showed no significant changes (Table 1).
Neither creatinine clearance nor urinary excretions (fractional
excretions, FE) of Na, K, Ca, P and uric acid showed any
significant differences from the control group. FEurea increased,
though not significantly, at the peak of diuresis in the high dose
group (Table 1).
The serum Na concentration (Fig. 4) rose only in the high dose
group by an average of 1.8 mEq!liter (3 hr), accompanied by an
increase in serum osmolality (Table 2). However, no significant
differences from the control group in the serum concentrations of
K, Ca, P, creatinine, urea and uric acid were associated with the
administration of OPC-31260 (data not shown).
The plasma AVP concentration rose significantly in the high
dose group (Fig. 5A), with significant increases in urinary AVP
excretion (Fig. SB). Urinary clearance of AVP was not signifi-
cantly altered at the peak of diuresis, but increased in parallel with
the rise of the plasma AVP concentration (Fig. SC).
No significant differences were observed among the three
groups in PRA, plasma aldosterone, angiotensin II, h-ANP,
norepinephrine and epinephrine concentrations, although aver-
age PRA was higher and the plasma h-ANP level was lower in the
high dose group after the diuretic stage (Table 2).
Urinary PGE2 excretion significantly increased with diuresis in
the high dose group. However, urinary TXB2 excretion showed a
tendency to decrease with time, and urinary 6-keto-PGF15 excre-
tion showed no significant change (Table 3); these two parameters
were not determined in the control and low dose groups because
of insufficient sample volume. Urinary nephrogenous cAMP
showed no significant change over time or among the three groups
(Table 3).
Administration of OPC-3 1260 caused no significant changes in
blood pressure or heart rate. However, regarding side effects, two
subjects in the high dose group complained of a slightly hot
sensation in the face, neck and chest for a duration of one or a few
minutes. One subject in the same group complained of a slight
palpitation immediately after OPC-31260 injection, and another
complained of slight dizziness at the time of urine voiding two
hours after the administration followed by 2½ hours of slight
sickness, but none showed any physical signs such as flushing. No
other side effects were noted.
Discussion
AVP acts on V2 receptors in the kidney to increase water
reabsorption, causing antidiuresis. In the present study, OPC-
31260, a non-peptide V2 antagonist, dose-dependently increased
urine volume and reduced urine osmolality in human subjects
Time after administration, hours
Fig. 3. Changes in free water clearance (CH2O) after OPC-31260 injection.
Symbols and statistical comparisons are the same as those in Figure 1.
Bars indicate mean SEM, N = 5.
under water restricted conditions, without any significant increase
in sodium and osmolar excretions. In the high dose group, the free
water excretion was equivalent to that previously reported in
normal subjects during maximum diuresis after water loading [11].
Thus, OPC-31260 exhibited a pure water diuretic (aquaretic)
action in vivo, indicating that it acts as a selective V2 antagonist in
humans. In this context, OPC-31260 is quite different from the
standard diuretics (saluretics), which increase both salt and water
excretion, the latter being secondary to the former.
According to a recent study, OPC-31260 caused water diuresis
in normally hydrated men who were hydrated by drinking 1100 ml
of barley tea (200 ml 1 hr before and 150 ml 2, 4, 6, 8, 9 and 12 hrs
after an intravenous administration of OPC-31260) [7]. While
OPC-3 1260 significantly lowered urinary osmolality, the average
urine osmolality in the control group remained around 300 to 500
mOsm/kg H20 throughout the study and it was obviously lower
than that in normal subjects who were allowed free access to water
[11]. These results did not necessarily ensure that OPC-31260
would cause water diuresis under hydropenic and antidiuretic
conditions. Rather, it may be probable that a V2 antagonist would
be less effective in hydropenia. However, the clinical circum-
stances in which an aquaretic would be useful would generally be
in patients with increased plasma AVP concentration and con-
centrated urine. Therefore, it is necessary to test the effect of
OPC-31260 on hydropenic subjects, in whom the plasma AVP
concentration is relatively increased and urine is almost maximally
concentrated. In the present study, OPC-31260 (1.0 mg/kg), in
fact, caused nearly maximal water diuresis in humans even under
these conditions, suggesting that the drug has a strong V2
antagonist effect in humans, with good promise for clinical
application.
Peptide V2 antagonists have been designed and developed by
Manning and Sawyer [1] and others [2, 3]. With respect to these
peptide V2 antagonists, species differences in aquaretic potency
have been recognized. For example, SK&F 101926 acted as a
potent aquaretic agent in rats, dogs and squirrel monkeys,
whereas it acted as an antidiuretic agent in rhesus monkeys and
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Table 1. Effects of OPC-31260 on osmolar clearance (COCm), creatinine clearance (Car), and fractional exretions of Na (FENa), K (FEK), calcium
(FEca), phosphate (FEe), uric acid (FECC acid) and urea (FEurea)
Time after administration hr
—2—0 0—0.5 0.5—1 1—1.5 1.5—2 2—3 3—4
C0 mi/mm C
L
H
1.8±0.3
2.1±0.3
2.8±0.9
2.5±0.4
3.5±0.5
3.3±0.5
2.1±0.3
2.8±0.4
2.5±0.4
1.8±0.2
2.4±0.5
2.1±0.4
1.9±0.3
2.3±0.5
2.2±0.5
1.8±0.2
2.1±0.3
2.1±0.4
1.7±0.2
1.8±0.3
1.9±0.4
Ccr mi/mm C
L
H
139 8
138 8
165 34
166 8
176 9b
173 13
149 6
158 6
133 10
143 9
144 7
137 19
151 8
150 4
133 6
145 6
144 4
129 6
150 6
148 6
129 6
FENa % C
L
H
0.47 0.08
0.80 0.14
0.81 0.18
0.62 0.12
1.01 0.15
0.79 0.19
0.62 0.12
0.93 0.15
0.67 0.21
0.53 0.08
0.95 0.23
0.62 0.17
0.51 0.09
0.88 0.25
0.79 0.24
0.49 0.08
0.78 0.19
0.86 0.24
0.49 0.11
0.60 0.12
0.79 0.22
FEK% C
L
H
6.3±2.4
6.3±1.3
7.4±1.2
7.9±2.8
10.3±2.9
10.4±2.0
7.9±2.3
9.8±2.3
11.3±2.4
7.3±2.0
9.1±2.0
10.1±2.5
7.2±1.6
7.9±1.6
9.3±2.6
6.7±1.4
7.0±1.2
7.7±2.0
6.5±1.1
5.9±1.1
6.5±1.8
FEca % C
L
H
0.77 0.12
0.94 0.10
0.72 0.14
0.65 0.14
0.79 0.07
0.55 0.14
0.57 0.13
0.59 0.03
0.30 0.14
0.51 0.11
0.57 0.09
0.21 0.04a
0.45 0.10
0.50 O.14
0.44 0.10
0.43 0.11
0.49 0.14a
0.52 0.12
0.39 0.14
0.40 007h
0.42 0.08
FE% C
L
H
6.7±0.8
5.9±0.8
9.3±1.1
5.5±1.0
4.9±0.5
6.8±0.7
5.0±0.9
4.7±0.6
5.5±0.9a
4.6±0.9
4.9±0.94708b
4.8±0.9
4.9±1.2
5.6±0.8a
5.3±1.0
5.6±1.0
6.9±1.0
6.2±0.9
6.0±1.0
7.6±1.0
FEurie % C
L
H
5.4 0.9
7.0±0.7
7.1±1.5
6.4 1.3
7.8±0.8
7.1±1.5
6.9 1.4
7.6±0.8
6.1±1.1
6.7 1.4
7.8±0.9
6.1±1.3
6.5 1.3
7.5±1.1
6.1±1.4
6.1 1.1
7.2±0.9
6.4±1.3
6.0 0.9
6.4±0.7
6.4±1.3
FEurea% C
L
H
48±11
37±3
54±16
46±8
48±5
57±2
43±6
46±7
81±26
35±4
37±4
48±4
31±2
32±3
42±4
32±3
33±2
594e
31±3
30±2
40±3
Abbreviations are: C, control group, L, low dose group (0.1 mg/kg); H, high dose group (1.0 mg/kg). Values are mean SEM, N = 5.
P < 0.05, bp < 0.01 compared with pre-injection value (—2—0 hr)
P < 0.01 compared with control group
—1 0 1 2 3
Time after administration, hours
dogs even in the presence of indomethacin, a cyclooxygenase
inhibitor [6].
The increased plasma AVP concentration in the high dose
group confirmed the predictions of previous reports, in which the
stimulation of AVP secretion by the rise in serum osmolality has
been shown [11, 13]. Also, increases in both urinary excretion and
clearance of AVP accompanying a rise in plasma AVP concen-
tration, similar to the results observed in this study, have already
been reported [14, 15]. Although urinary AVP clearance is not
altered at the peak of diuresis, there is also the possibility that
AVP inactivation is delayed by V2 antagonist [16], since its
metabolism and accumulation in the kidneys is in part receptor-
mediated [17, 181.
The tendencies for an increase in PRA and a decrease in
h-ANP seen in the high dose group may reflect a reduction in
body fluid volume due to water excretion [19], since they became
evident towards the end of this experimental protocol.
In this study, OPC-3 1260 caused no significant change in Na
excretion. On the other hand, increased Na excretion was dem-
onstrated in rats by OPC-3 1260 [6] and peptide V2 antagonists
[20] but not in dogs [21] or rhesus monkeys [22]. In contrast to
rats, humans and dogs lack AVP-sensitive adenylate cyclase
activity in the thick ascending limb (TAL) of Henle [23, 241.
Therefore, the increased Na excretion by the V2 antagonists in the
rats may reflect an inhibition of V2 receptor dependent reabsorp-
tion of NaCl in the TAL. This is consistent with reported results
that a physiological dose of AVP or DDAVP has no effect on Na
excretion in humans [25, 261. On the contrary, water diuresis
develops and subsides without any significant changes in Na
excretion, although some reports show an increase in Na excretion
L.
LU
E
z(I)
143
142
141
140
139
138
Fig. 4. Effect of OPC-31260 on semm Na concentration (SNa). Symbols
and statistical comparisons are the same as those in Figure 1. Bars indicate
mean SEM, N = 6.
humans [4, 5]. Such species heterogeneity was assumed to be
associated with a partial V2 agonistic effect of the V2 antagonists
and with species differences in V2 receptor sensitivity. Renal
cyclooxygenase tone was suggested to be an important determi-
nant of the sensitivity [121. It seems likely, therefore, that OPC-
31260 caused aquaresis in humans because it exhibits absolutely
no agonist activity in rats either in vitro or in vivo, and in hydrated
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those of a previous study [71 in which OPC-31260 (1.0 mg/kg)
caused a significant increase in Na excretion during the first four
hours (placebo, 48.6 4.2; OPC-31260, 70.4 4.5 mEq/4 hr).
The difference might have been greater at the peak of diuresis (30
to 60 mm after administration of OPC-3 1260) if the urine samples
had been collected at shorter intervals. The reason for this
difference is not clear; however, urinary Na was measured by ion
electrode method using an autoanalyzer equipped with ion selec-
tive electrodes in the previous study and by flame photometry in
this study. In this connection, we measured the same urine
samples using the two kinds of methods and found that, in the
urine nearly maximally diluted, the autoanalyzer gave higher value
than that measured by the flame photometer, and the Na concen-
tration was unreasonably higher than that expected from the
urinary osmolality calculated by the following formula [urinary
osmolality (mOsm/kg H20) = 2 (Na + K) (mEq/liter) + urea
(mM/liter)]. In any case, further studies are necessary regarding
the Na excretion, because the condition of hydration was also
different between the previous study and this study.
The observed increase in urea excretion during diuresis may be
explained by the V2-antagonistic effect of OPC-31260 on urea
reabsorption by AVP [28, 29]. The increase in urinary PGE2
excretion in the high dose group is consistent with previous
findings where it occurs in water diuresis [30, 31], and where it
depends largely on the urine flow rate [32]. On the other hand,
neither 6-keto-PGF1,, nor TXB2 excretion increased during diure-
sis, suggesting that further studies will be necessary.
In this study, the V2 antagonist did not alter nephrogenic cAMP
excretion, which was predictable from the result that DDAVP did
not increase urinary cAMP in patients with diabetes insipidus [271.
Thus, most of the observed effects of OPC-3 1260 are consistent with
those which were predicted for an antagonist of renal V2 receptors.
Clinically, there are many pathological conditions in which
AVP plays an important role in causing water retention. For
example, excessive AVP release is involved in the mechanism of
Table 2. Effects of OPC-31260 on serum osmolality (P0m), plasma renin activity (PRA) and plasma concentrations of aldosterone, angiotensin II,
atrial natriuretic peptide (h-ANP), norepinephrine and epinephrine
Time after administration hr
—0.5 1 2 3 4
Osm mOsm/kgH2O C
L
H
281.8 1.3
282.8 1.1
279.8 1.9
282.3 1.8
284.0 1.8
282.7 1.3
280.7 1.1
281.5 1.2
283.2 1.3
280.7 1.2
280.2 1.0
282.3 1.3
280.8 1.0
280.7 1.0
281.8 1.7
PRA ng/ml/hr C
L
H
1.5 0.4
1.4 0.3
1.4 0.4
1.5 0.4
1.2 0.2
1.9 0.5
2.2 0.5
1.5 0.2
2.2 0.5
2.1 0.5
1.9 0.3
2.9 0.8
2.1 0.6
1.9 0.4
3.1 0.8
Aldosteronepg/mi C
L
H
104 17
77±15
81±11
61 8
72±13
70±7
65 11
72±16
81±12
68 11
74±15
94±15
67 10
80±17
85±14
Angiotensin II pg/mi C
L
H
16.7 2.7
29.7 9.9
18.9 4.7
15.4 1.9
12.9 2.2
18.4 6.3
16.2 2.1
17.5 3.8
19.0 6.1
15.2 2.7
18.1 3.0
18.9 7.1
15.0 2.2
19.4 4.0
19.6 4.9
h-ANP pg/mi C
L
H
10.4 1.5
9.5 1.9
9.2 0.9
10.8 1.5
11.5 2.8
7.7 0.7
10.7 1.7
10.0 1.9
8.0 0.9
9.7 1.2
9.9 1.6
7.5 0.4
8.4 0.6
8.7 1.1
6.6 0.6
Norepinephrine pg/mi C
L
H
90.3 7.8
76.7 8.7
77.0 10.3
86.2 7.0
80.7 9.6
84.3 13.3
89.7 5.6
69.3 5.0
82.7 7.4
84.7 9.1
80.3 8.6
78.5 11.5
85.7 6.2
71.2 4.5
81.5 3.1
Epinephrine pg/mi C
L
H
14.0 2.1
14.8 2.9
11.3 0.7
19.2 5.9
23.3 10.3
13.3 1.5
21.7 8.6
20.0 5.9
16.2 3.0
20.3 8.0
20.8 6.8
12.8 1.9
25.0 6.8
24.2 7.8
17.5 4.3
A
Abbreviations are: C, control group; L, low dose group (0.1 mg/kg); H, high dose group (1.0 mg/kg).
No significant differences were detected. Values are mean SEM, N = 6.
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Fig. 5. Effects of OPC-31260 on (A) plasma A VP Concentration (P-A VP),
(B) urina,yA VP excretion (U-A VP) and (C) urina,yAVP clearance (C4).
Symbols and statistical comparisons are the same as those in Figure 1.
Bars indicate mean SEM, N = 6 (A) or 5 (B and C).
[27]. These differences may depend on the volume status, but the
exact interpretation of the differences still remains unclear.
Regarding Na excretion, the results of this study differed from
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Table 3. Effects of OPC-31260 on urinary excretions of prostagrandin E2 (PGE2), thromboxane B2 (TXB2) and 6-keto prostagrandin F1,, (6-keto-
PGF1,,), and nephrogenous cyclic AMP (NcAMP)
Time after administration hr
—2—0 0—0.5 0.5--i 1—1.5 1.5—2 2—3 3—4
PGE2pg/min C
L
H
64±11
66 13
77 28
72±13
144 48
154 50
67±13
140 64
338 ioia
55±690 9
266 83"
51±8
69 16
148 55
48±5
61 10
76 15
54±11
67 13
59 14
TXB2pgImin H 404 40 409 66 231 31 319 90 281 48 307 57 245 31
6-keto-PGF,,,pg/min H 773 132 640 48 659 145 551 58 445 34 413 27 468 65
NcAMP nmol/ml C
L
H
1.4 0.2
1.3±0.2
1.2±0.2
1.6 0.1
1.5±0.2
1.3±0.2
1.5 0.2
1.3±0.2
1.5±0.3
1.5 0.1
1.3±0.2
1.4±0.4
1.4 0.2
1.4±0.2
1.5±0.2
1.5 0.3
1.4±0.2
1.3±0.1
1.5 0.2
1.4±0.2
1.4±0.2
C, control group; L, low dose group (0.1 mg/kg); H, high dose group (1.0 mg/kg).
aP < 0.05 compared with pre-injection value (—2—0 hr)b P < 0.05 compared with control group
Values are mean SEM, N 5.
hyponatremia in SIADH [33, 34] and in edematous diseases such
as congestive heart failure and cirrhosis of the liver [35]. Peptide
V2 antagonists have been used to evaluate the role of AVP in
animal models of hyponatremia [2, 3], and the therapeutic efficacy
of a peptide V2 antagonist [36] and OPC-3 1260 [37] has been
demonstrated in a rat model of SIADH. OPC-31260 will probably
be useful as the therapeutic treatment for clinical hyponatremia,
unless it shows severe side effects. Moreover, since OPC-31260 is
also effective by oral administration [6], it is expected that the
drug will be well-suited for more chronic therapy than that
expected from intravenous administration.
In conclusion, OPC-31260 exhibited a dose-dependent V2
antagonist action, that is, aquaretic action, in hydropenic humans
with endogenous AVP secretion and maximally concentrated
urine. The drug will be useful as an aquaretic in the treatment of
hyponatremia and water retention.
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